PROGRAMME
Gene therapy
Chairs: Brian O’Mahony (Ireland), Antonia Follenzi (Italy)
09:00
Gene therapy in haemophilia A and B: summaryDavid Lillicrap (Canada)
09:20
FVIII-induced endoplasmic reticulum (ER) stress in the context of gene therapyRandal J. Kaufman (US)
09:40
Lentiviral factor VIII gene therapy: where we are standing
Alessio Cantore (Italy)
10:00
Discussion
Round table
Chairs: Flora Peyvandi (Italy), David Lillicrap (Canada)
10:10
Gene therapy: calculating the unknown
Discussants: Declan Noone (Ireland),
Brian O’Mahony (Ireland),
Glenn Pierce (US)
10:40
Coffee break
Haemophilia
Chairs: Peter Lenting (France), Angiola Rocino (Italy)
11:10
Engineering of novel factor VIII molecules: how we could improve the next moleculesLindsey George (US)
11:30
Nanobodies as diagnostic and therapeutic tools in haemostasisPeter Lenting (France)
11:50
Discussion
Satellite Lecture
12:00
Roche
PROGRAMME
Satellite Lecture
12:30
Sanofi Genzyme
PROGRAMME
13:00
Lunch
Satellite Symposium
14:00
Takeda
PROGRAMME
Oral Communications
Chairs: Cecile Denis (France), Augusto B. Federici (Italy)
15:00
Transplacental delivery of maternal maternal factor VIII for induction of maternal factor VIII-specific immune tolerance
Angelina Mimoun (France)
15:10
N-glycan shielded rhADAMTS13 for treatment of immune thrombotic thrombocytopenic purpura
Nuno A. G. Graça (The Netherlands)
15:20
Anti-cysteine/spacer autoantibodies that open the conformation of ADAMTS13 are a common feature of the autoimmune response in immune-mediated thrombotic thrombocytopenic purpura
Laure De Waele (Belgium)
15:30
From coagulation to angiogenesis: possible role of factor VIII in endothelial functionality
Cristina Olgasi (Italy)
15:40
Syntaxin 5 is essential for Golgi integrity, Weibel-Palade body biogenesis and stimulus-induced von Willebrand factor secretion from endothelial cells
Marije Kat (The Netherlands)
15:50
Developing a model for studying von Willebrand disease with hiPSC-derived endothelial cells
Suzan De Boer (The Netherlands)
16:00
Coffee break
16.30
E-POSTER SESSION
PROGRAMME
Non replacement therapies: novel drugs
Chairs: Jan Voorberg (The Netherlands)
17:30
Antithrombin knockdown: tipping the balance of haemostasis and thrombosisMargaret V. Ragni (US)
17:50
Rebalancing haemostasis by inhibiting Activated Protein C (APC)Jim Huntington (UK)
18:10
Discussion
18:20
Wrap up and closing remarksFlora Peyvandi (Italy),
Pier Mannuccio Mannucci (Italy)